| 1 |
黄洁夫. 《中国器官捐献和移植发展报告（2024）》[M]. 北京: 清华大学出版社, 2025.
|
| 2 |
Chen-Yoshikawa TF. Ischemia-Reperfusion Injury in Lung Transplantation[J]. Cells, 2021, 10(6): 1333.
|
| 3 |
Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation[J]. J Heart Lung Transplant, 2018, 37(10): 1169-1183.
|
| 4 |
Oishi H, Okada Y, Sato M, et al. Prognostic factors for lung transplant recipients focusing on age and gender: the Japanese lung transplantation report 2022[J]. Surg Today, 2023, 53(10): 1188-1198.
|
| 5 |
戴振航, 王梓涛, 陈静瑜. 中国肺移植发展现状概述及未来展望[J]. 中国研究型医院, 2024, 11(6): 32-36.
|
| 6 |
Jiao W, Yang R, Zhao Y, et al. Robot-assisted single lung transplantation[J]. Chin Med J (Engl), 2023, 136(3): 362-364.
|
| 7 |
Gao R, Wang W, Qian T, et al. Pulmonary bacterial infection after lung transplantation: risk factors and impact on short-term mortality[J]. J Infect, 2024, 89(5): 106273.
|
| 8 |
Lv J, Zhou M, Wei D, et al. Analysis of high-risk factors for early pulmonary bacterial infection after lung transplantation and their correlation with long-term mortality[J]. Am J Transl Res, 2024, 16(9): 4988-4995.
|
| 9 |
Lee KH, Jeong SJ, Kim SY, et al. Effects of Multidrug-resistant Bacteria in Donor Lower Respiratory Tract on Early Posttransplant Pneumonia in Lung Transplant Recipients Without Pretransplant Infection[J]. Transplantation, 2020, 104(4): e98-e106.
|
| 10 |
Bunsow E, Los-Arcos I, Martin-Gómez MT, et al. Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance[J]. J Infect, 2020, 80(2): 190-196.
|
| 11 |
Li Y, Li X, Wu W, et al. Insights into the roles of macrophages in Klebsiella pneumoniae infections: a comprehensive review[J]. Cell Mol Biol Lett, 2025, 30(1): 34.
|
| 12 |
Ferrara F, Pasquinucci R, Capuozzo M, et al. Comparison and Analysis of Antibiotic Consumption in Two Italian Hospital Settings in Relation to the Fight of Antimicrobial Resistance[J]. Pharmaceuticals (Basel), 2024, 17(2): 183.
|
| 13 |
Weigt SS, Kim GJ, Jones HD, et al. Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts Mortality[J]. Transplantation, 2022, 106(6): 1253-1261.
|
| 14 |
Todd JL, Neely ML, Finlen Copeland CA, et al. Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction[J]. J Heart Lung Transplant, 2019, 38(2): 184-193.
|
| 15 |
Sundaresan S, Trulock EP, Mohanakumar T, et al. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group[J]. Ann Thorac Surg, 1995, 60(5): 1341-1346.
|
| 16 |
Costa J, Benvenuto LJ, Sonett JR. Long-term outcomes and management of lung transplant recipients[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(2): 285-297.
|
| 17 |
Verleden SE, Vos R, Vanaudenaerde BM, et al. Chronic lung allograft dysfunction phenotypes and treatment[J]. J Thorac Dis, 2017, 9(8): 2650-2659.
|
| 18 |
Levy L, Huszti E, Renaud-Picard B, et al. Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system[J]. J Heart Lung Transplant, 2020, 39(8): 761-770.
|
| 19 |
Van Herck A, Verleden SE, Sacreas A, et al. Validation of a post-transplant chronic lung allograft dysfunction classification system[J]. J Heart Lung Transplant, 2019, 38(2): 166-173.
|
| 20 |
Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction[J]. J Heart Lung Transplant, 2011, 30(7): 735-742.
|
| 21 |
Bedair B, Hachem RR. Management of chronic rejection after lung transplantation[J]. J Thorac Dis, 2021, 13(11): 6645-6653.
|
| 22 |
Corris PA, Ryan VA, Small T, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation[J]. Thorax, 2015, 70(5): 442-450.
|
| 23 |
Vos R, Wuyts WA, Gheysens O, et al. Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series[J]. Am J Transplant, 2018, 18(12): 3045-3059.
|
| 24 |
Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report-2019; focus theme: Donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1056-1066.
|
| 25 |
Bhat M, Usmani SE, Azhie A, et al. Metabolic Consequences of Solid Organ Transplantation[J]. Endocr Rev, 2021, 42(2): 171-197.
|
| 26 |
Lee J, Yang AWJ, Chung LI, et al. A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation[J]. Transpl Int, 2023, 36: 11552.
|
| 27 |
Stubber C, Kirkman M. The experiences of adult heart, lung, and heart-lung transplantation recipients: A systematic review of qualitative research evidence[J]. PLoS One, 2020, 15(11): e0241570.
|
| 28 |
Pesce de Souza F, Massierer D, Anand Raje U, et al. Exercise interventions in solid organ transplant candidates: A systematic review[J]. Clin Transplant, 2020, 34(9): e13900.
|
| 29 |
Ali A, Wang A, Ribeiro RVP, et al. Static lung storage at 10 ℃ maintains mitochondrial health and preserves donor organ function[J]. Sci Transl Med, 2021, 13(611): eabf7601.
|
| 30 |
Aigner C, Slama A, Hötzenecker K, et al. Clinical ex vivo lung perfusion—pushing the limits[J]. Am J Transplant, 2012, 12(7): 1839-1847.
|
| 31 |
Reynolds M, Walsh MG, Cui EY, et al. Extended travel for donor organs: Is cold static storage still relevant[J]. World J Transplant, 2025, 15(3): 102150.
|
| 32 |
Sunder T. Extracorporeal membrane oxygenation and lung transplantation[J]. Indian J Thorac Cardiovasc Surg, 2021, 37(Suppl 2): S327-S337.
|
| 33 |
Fritz AV, Teixeira MT, Patel SJ, et al. Update in lung transplantation: anesthetic considerations[J]. Ann Transl Med, 2023, 11(11): 389.
|
| 34 |
Kawashima M, Ijiri N, Konoeda C, et al. Extended Use of Central Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Pulmonary Arterial Hypertension[J]. Eur J Cardiothorac Surg, 2025, 67(8): ezaf256.
|
| 35 |
Martin AK, Mercier O, Fritz AV, et al. ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part Ⅱ: Intraoperative Considerations[J]. J Heart Lung Transplant, 2026, 45(1): e35-e62.
|
| 36 |
Toyoda T, Thomae BL, Kandula V, et al. Primary graft dysfunction grade correlates with acute kidney injury stage after lung transplantation[J]. J Thorac Dis, 2023, 15(7): 3751-3763.
|
| 37 |
Komine N, Satoh S, Saito M, et al. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients[J]. Int Immunopharmacol, 2018, 58: 57-63.
|
| 38 |
Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing[J]. Clin Pharmacol Ther, 2015, 98(1): 19-24.
|
| 39 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2004, 43(10): 623-653.
|
| 40 |
Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management[J]. Clin Transplant, 2003, 17(2): 77-88.
|
| 41 |
Alnababteh M, Keller MB, Kong H, et al. Early post-transplant recipient tissue injury predicts allograft function, rejection and survival in lung transplant recipients: evidence from cell-free DNA[J]. Eur Respir J, 2026, 67(4): 2402537.
|
| 42 |
Hou F, Qiao Y, Qiao Y, et al. A retrospective analysis comparing metagenomic next-generation sequencing with conventional microbiology testing for the identification of pathogens in patients with severe infections[J]. Front Cell Infect Microbiol, 2025, 15: 1530486.
|
| 43 |
Todd JL, Weber JM, Kelly FL, et al. Early posttransplant reductions in club cell secretory protein associate with future risk for chronic allograft dysfunction in lung recipients: results from a multicenter study[J]. J Heart Lung Transplant, 2023, 42(6): 741-749.
|
| 44 |
Agbor-Enoh S, Wang Y, Tunc I, et al. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation[J]. EBioMedicine, 2019, 40: 541-553.
|
| 45 |
Keller MB, Tian X, Jang MK, et al. Higher Molecular Injury at Diagnosis of Acute Cellular Rejection Increases the Risk of Lung Allograft Failure: A Clinical Trial[J]. Am J Respir Crit Care Med, 2024, 209(10): 1238-1245.
|
| 46 |
Keller M, Bush E, Diamond JM, et al. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD)[J]. J Heart Lung Transplant, 2021, 40(6): 488-493.
|
| 47 |
Gan CT, Ward C, Meachery G, et al. Long-term effect of azithromycin in bronchiolitis obliterans syndrome[J]. BMJ Open Respir Res, 2019, 6(1): e000465.
|
| 48 |
Singh TP, Hsich E, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2025, 44(12): 1857-1873.
|